Navigation Links
Novartis launches Arcapta™ Neohaler™, a novel once-daily bronchodilator for chronic obstructive pulmonary disease
Date:3/19/2012

n people in the US are affected, while another estimated 12 million people are believed to have the disease but remain undiagnosed. COPD ranks as the third leading cause of death in the US and is a major cause of serious long-term disability. Arcapta Neohaler has not been shown to impact mortality or long-term disability caused by COPD.

According to 2011 GOLD Guidelines, bronchodilators are central to COPD management. Bronchodilators have different mechanisms of action and long-acting beta2-agonists (LABA) are among the classes of bronchodilators.

"The COPD Foundation is dedicated to providing information and support individuals with COPD," said John W. Walsh, president and co-founder of the US-based COPD Foundation. "The availability of this new, once-daily LABA is good news for COPD patients looking for new treatment options and for the millions of Americans that are living with this serious disease."

Once-daily Arcapta Neohaler also reduced the need for patients to use short-acting beta2-agonists (albuterol) as rescue therapy, measured as a secondary endpoint. Additionally, Arcapta Neohaler is the only COPD treatment approved with demonstrated improvements in health-related quality of life, as measured by the St George's Respiratory Questionnaire (SGRQ). The SGRQ is a disease-specific, patient-reported instrument that measures health-related quality of life for symptoms, activities and impact of daily life.

The safety and tolerability of Arcapta Neohaler was assessed in a clinical program of more than 5,400 COPD patients, with more than 2,500 who received Arcapta Neohaler for at least 12 weeks at doses of 75 mcg or higher. Adverse reactions were reported by 48% of patients treated with any dose of Arcapta Neohaler compared with 43% of patients treated with placebo. The most common serious adverse reactions were COPD exacerbation, pneumonia, angina pectoris, and atrial fibrillation, which occurred at similar rates across t
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data in NEJM shows Novartis drug Signifor® is first therapy to provide rapid, durable benefit for Cushings disease patients in Phase III study
2. FDA approves Novartis drug Gleevec® label recommending extending treatment to three years for certain GIST patients after surgery
3. Unity Management Group Subsidiary Announces First Contracts of 2012 with Purdue Pharma L.P. and Novartis
4. Endo Announces Potential Short-Term Supply Constraints of Certain Analgesic Medications as a Result of Temporary Shut Down of Novartis Facility
5. Novartis Consumer Health Inc. Issues Voluntary Nationwide Recall of Certain Over-the-Counter Products Due to Potential Presence of Foreign Tablets or Chipped or Broken Tablets or Gelcaps
6. Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec®
7. New Data Confirms Novartis Drug Afinitor® Significantly Extends Time Women With Advanced Breast Cancer Live Without Tumor Growth
8. Novartis Study Shows QTI571 Significantly Improved Walking Distance in Patients with Life-Threatening Pulmonary Arterial Hypertension
9. Novartis Drug Afinitor® Effective in Patients With Non-Cancerous Kidney Tumors Associated With TSC in Phase III Trial
10. Novartis Study Showed ACZ885 Provided Substantial Symptom Relief in 84% of Patients With the Most Serious Form of Childhood Arthritis
11. Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)...  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... the sale to Galderma of all rights to Restylane, ... Valeant for $1.4 billion in cash, pursuant to the ... its acquisition of Galderma. "We are ... a company that is firmly committed to the aesthetic ...
(Date:7/10/2014)... July 10, 2014   LabStyle Innovations Corp ... today announced the appointment of Professor Richard ... its Board of Directors. Prof. Stone ... experience to LabStyle as an entrepreneur, venture capitalist ... corporate governance expert. He currently serves on the ...
(Date:1/15/2014)... , Jan. 15, 2014 Sono-Tek Corporation (OTC BB: SOTK) ... November 30, 2013, compared to sales of $2,202,000 for the ... again, this quarter has also shown growth over the preceding ... quarter of this fiscal year. Markets that experienced sales increases ...
Breaking Medicine Technology:LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4
(Date:7/13/2014)... type-1 diabetes could improve patient care worldwide and ... the device,s inventors at the Stanford University School ... be published online July 13 in Nature ... type-1 diabetes outside hospital settings. The handheld microchips ... mellitus, which are both characterized by high blood-sugar ...
(Date:7/13/2014)... American water storage systems market is estimated to grow from ... a CAGR of 21.0%, from 2013 to 2018. The water ... North America. The U.S. is experiencing high growth on account ... collection, and the increased spending on modernization and upgradation of ... in Canada, and is rising at a rapid pace in ...
(Date:7/13/2014)... 13, 2014 Fuel additives are chemicals, ... diesel, jet fuel, kerosene, and so on, in order ... for reducing the corrosion effects caused by fuels and ... to any fuel, provide economies of scale in the ... the overall cost of the fuel products. , The ...
(Date:7/13/2014)... HealthDay Reporter FRIDAY, July 11, ... for people with diabetes is being developed to measure sugar ... report. Scientists at Brown University in Providence, R.I., created ... uses light, metal and a special enzyme that changes color ... have to prick their fingers to draw blood to check ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Recently, ... retailer, has unveiled its new range of gorgeous ... current market, the demand for elegant Quinceanera outfits ... more beautiful items. All the company’s newly released ... trends. They are all elegant and vivid. ...
Breaking Medicine News(10 mins):Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 2Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 3Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 4Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 2Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 2Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 4Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 2Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 3Health News:2014QuinceaneraDresses.com Releases Its New Quinceanera Dresses 2
... presented innovative, early-stage research at the 16th Annual ... AUA Foundation and the Society for Basic Urologic ... Foundation hosted the forum for young investigators to ... sexual medicine. These investigators represent the future ...
... Clinical Team Conference on October 23,2008, ALEXANDRIA, ... to improving America,s future. A strong advocate for,children ... vocal advocate and,tireless worker on behalf of important ... Mrs. Edwards will be the opening speaker at,the ...
... men with enlarged prostates, daily Cialis showed benefit without ... -- A daily dose of the erectile dysfunction drug ... men with signs of enlarged prostates, according to a ... age 50 and older have lower urinary tract symptoms, ...
... saves hospital money, enables more wide-spread ... authentication for network access, DALLAS, ... Medical Center already was,leveraging two-factor authentication via hardware tokens in ... The,solution, however, was cost-prohibitive to deploy to a wider audience ...
... ... Practitioners, NEWPORT BEACH, Calif., ... a Managed Compliance Services,Program (MCSP) for small healthcare practitioners -- the ... Program is tailored to meet the HIPAA compliance,requirements of small healthcare ...
... reach 210,000 cups sold by Labor Day ... 2008, First-of-its-kind virtual lemonade stand ... ... the,fight to eliminate pediatric cancer charges ahead. The world,s first,virtual lemonade stand, http://www.lemonadestandforlife.com ...
Cached Medicine News:Health News:New research on sexual function 2Health News:Elizabeth Edwards to be Opening Speaker at National Hospice Conference in Dallas 2Health News:ED Drug Relieves Lower Urinary Tract Symptoms 2Health News:Entrust IdentityGuard Enables Georgia-based Hospital Network to Deploy Strong Authentication for Remote Access 2Health News:Entrust IdentityGuard Enables Georgia-based Hospital Network to Deploy Strong Authentication for Remote Access 3Health News:Managed Compliance Services Program (MCSP) Introduced for Small Healthcare Practitioners 2Health News:Managed Compliance Services Program (MCSP) Introduced for Small Healthcare Practitioners 3Health News:Make an Impact on Pediatric Cancer Research Before Summer's End: Try Some Virtual Lemonade! 2Health News:Make an Impact on Pediatric Cancer Research Before Summer's End: Try Some Virtual Lemonade! 3
The Bair Hugger outpatient blanket makes it easy to give your patients the benefit of prewarming and enhance patient comfort during outpatient procedures....
Cocoon Disposable Patient Warming Blankets are specially designed to prevent hypothermia and maintain normothermia in your patients. The soft warm coloured material is strong and resists tearing and ...
2-ply material consisting of polyethylene film inner layer and non-woven outer layers....
The upper body blanket is typically used for abdominal or lower body procedures. The upper body blankets warms the upper torso and arms. A clear drape is included to cover and warm the intubated pati...
Medicine Products: